Tigecycline Overview and Liver Risk
Tigecycline, a glycylcycline antibiotic used for complicated skin/skin structure infections, intra-abdominal infections, and community-acquired pneumonia, carries warnings for liver-related adverse events. Clinical trials and post-marketing data show elevated liver enzymes (ALT/AST) in 1-15% of patients, with rare cases of severe hepatic injury, including hepatitis and liver failure.[1][2]
Common Liver-Related Side Effects
Patients often experience asymptomatic transaminase elevations, typically mild to moderate (up to 3x upper limit of normal). In phase 3 trials, 15% of tigecycline-treated patients had ALT increases vs. 10% in comparators. Severe cases (ALT >10x normal) occurred in <1%, resolving after discontinuation. Nausea/vomiting, common overall (20-30%), can mimic early liver issues but are gastrointestinal, not hepatic.[1][3]
Severe Liver Risks and Case Reports
Rare idiosyncratic hepatotoxicity includes acute liver injury, cholestasis, and failure, sometimes fatal. FDA labeling notes post-marketing reports of hepatic failure, often in patients with comorbidities like diabetes or alcohol use. Risk appears dose-dependent; higher doses (100mg loading then 50mg BID) correlate with more events. A 2010 review found tigecycline among antibiotics linked to drug-induced liver injury (DILI), with latency of days to weeks.[2][4]
Risk Factors and Who Is Most Affected
Higher risk in those with preexisting liver disease (Child-Pugh B/C), obesity, or concurrent hepatotoxins (e.g., acetaminophen). Trials excluded severe liver impairment, so real-world data shows caution advised; monitor LFTs closely. No clear genetic predictors identified, but prolonged use (>14 days) increases odds.[1][5]
Monitoring and Management Guidelines
Baseline and weekly LFTs recommended during treatment. Discontinue if ALT >5x normal with symptoms (jaundice, fatigue) or >3x with bilirubin >2x normal. FDA black box warns of increased mortality risk (4% vs. 3% comparators), partly hepatic-related. Alternatives like meropenem preferred for liver-compromised patients.[1][3]
Comparison to Other Antibiotics
Tigecycline's liver risk exceeds comparators like vancomycin (1-5% transaminitis) or linezolid (<2%), but matches some broad-spectrum agents (e.g., piperacillin-tazobactam at 5-10%). Unlike amoxicillin-clavulanate (top DILI cause), tigecycline events are less cholestatic, more hepatocellular.[4][6]
[1]: FDA Tigecycline Label
[2]: Hepatic Safety of Tigecycline
[3]: Tygacil Prescribing Information
[4]: DILI Database - Tigecycline
[5]: Risk Factors for Tigecycline Hepatotoxicity
[6]: Antibiotic Hepatotoxicity Review